Drugs / INBRX-106
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04198766 | Dec 2019 → Oct 2026 expected | gastric cancer, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06353997 | Sep 2024 → Jun 2027 expected | triple-negative breast carcinoma | Providence Health & Services | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06295731 | May 2024 → May 2029 expected | head and neck squamous cell carcinoma | Inhibrx Biosciences, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Inhibrx Biosciences, Inc | Results Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study investorroom.com ↗
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone |
| 2026-05-18 | Elpiscience Biopharma, Ltd. | Results Interim Phase 2 Data for Hexavalent OX40 Agonist Combination Therapy in First-Line HNSCC Demonstrate Potential Benefit Over PD-1 Monotherapy elpiscience.com ↗
Data showed that in first-line HNSCC patients with high PD-L1 expression, the combination treatment group achieved a confirmed objective response rate (cORR) of 44.0%, approximately double that observed with PD-1 monotherapy (21.4%). |
| 2026-05-11 | Inhibrx Biosciences, Inc | Results Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy investorroom.com ↗
In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR. |
| 2022-01-04 | Inhibrx Biosciences, Inc | Results Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data investorroom.com ↗
INBRX-106 in combination with Keytruda ® was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted. |
| 2021-06-25 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces CDE Clearance of IND Application for ES102 in Combination of Toripalimab elpiscience.com ↗
the Center of Drug Evaluation (CDE) has approved the IND application for ES102, a next generation anti-OX40 antibody, in combination with toripalimab (TUOYI®) an anti-PD1 antibody, in patients with advanced solid tumor. |
| 2021-01-05 | Inhibrx Biosciences, Inc | Results Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist investorroom.com ↗
In this Phase 1 trial, INBRX-106 was observed to be well tolerated, with mostly mild or moderate immune-related toxicities noted, in line with the mechanism of action of this candidate therapeutic. |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INBRX-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04198766 ↗ |
| Action | Activate | “hexavalent OX40 agonist antibody” NCT04198766 ↗ |
| Route | Intravenous | “INBRX-106 by intravenous (IV) infusion” NCT06295731 ↗ |
| Target | TNFRSF4 | “targets the human OX40 receptor (TNFRSF4)” NCT04198766 ↗ |